BioStem Technologies, Inc., a MedTech company that makes products from the placenta for advanced wound care, has named Brandon Poe as its new Chief Financial Officer. Poe has been part of BioStem’s Board of Directors since 2022, and this move comes at an important time for the company’s growth. Michael Fortunato, who was previously the CFO, will now take on the role of Chief Accounting Officer.
Health Technology Insights: Qualtrics, Stanford Health Use AI to Improve Care
Jason Matuszewski, the Chairman and CEO of BioStem, is confident about this decision. “I’m excited to have Brandon as CFO during this key time for BioStem,” Matuszewski said. “Brandon has strong financial leadership experience in life sciences, medical devices, and healthcare services, with expertise in capital markets, strategic planning, and operational excellence. His work on the Board has already been valuable, and his deep knowledge of our business will help us as we enter new markets, move forward with our Nasdaq listing, and achieve our long-term goals.”
Poe has more than 25 years of experience in finance within the healthcare and life sciences industries. Most recently, he was the CFO at Midi Health, a private company focused on women’s health care. Before that, he was the CFO at Jumpcode Genomics, a private life sciences firm. Earlier in his career, Poe worked for eight years at Illumina, Inc., a publicly traded company, where he held several senior finance roles, including Vice President of Finance for Product Development, Research, and Global Operations. He received his undergraduate degree from Bucknell University and his MBA from the Booth School of Business at the University of Chicago.
Health Technology Insights: Talkiatry Adds Two Chief Psychiatrists to Leadership Team
Brandon Poe expressed his excitement about joining BioStem’s leadership team. “BioStem is a leader in innovative wound care technologies, and I’m thrilled to be CFO during this critical phase of the company’s growth,” Poe said. “With the strong BioREtain platform, scalable manufacturing, and growing clinical evidence, we are well-positioned to grow and expand our market presence. I look forward to working with this talented team to carry out our strategy and create value for our shareholders.”
With Poe taking on this role, BioStem is preparing to scale its innovations and business development, matching its financial leadership with the next stage of its growth and commercial progress.
Health Technology Insights: HFSA Launches Nation’s First Comprehensive Heart Failure Clinic Database
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
